(Q40654818)

22 September 2017

R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis (English)

1 reference

22 September 2017

Dan Ye

1

1 reference

22 September 2017

Shenghong Ma

series ordinal

2

1 reference

22 September 2017

Yue Xiong

series ordinal

3

1 reference

22 September 2017

Kun-Liang Guan

series ordinal

4

1 reference

22 September 2017

1 March 2013

1 reference

22 September 2017

1 reference

22 September 2017

23

1 reference

22 September 2017

3

1 reference

22 September 2017

274-276

1 reference

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Alterations of metabolic genes and metabolites in cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

Expanding chemical biology of 2-oxoglutarate oxygenases

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3652525

10.1016/J.CCR.2013.03.005

22 September 2017

Identifiers

DOI

1 reference

release_bkhlk473rbezvjpkhgbwimbjdm

22 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bkhlk473rbezvjpkhgbwimbjdm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

22 September 2017

PubMed publication ID

23518346

1 reference